Aspira Women's Health (AWH) said late Tuesday that the New York State Department of Health's Clinical Laboratory Evaluation Program has approved OvaWatch, its non-invasive blood test for ovarian cancer risk assessment.
The company said the approval allows OvaWatch to be marketed in New York state.
Shares of the company were up 2% in after-hours activity.
Price: 0.8000, Change: +0.02, Percent Change: +2.04
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。